National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States

Objectives: To determine antimicrobial nonsusceptibility rates for Enterobacteriaceae and Acinetobacter spp. in US hospitals. Methods: We analyzed antimicrobial susceptibilities of non-duplicate Enterobacteriaceae and Acinetobacter spp. isolates reported in 2017 from 375 US hospitals in the BD Insig...

Full description

Bibliographic Details
Main Authors: Vikas Gupta, Gang Ye, Melanie Olesky, Kenneth Lawrence, John Murray, Kalvin Yu
Format: Article
Language:English
Published: Elsevier 2019-08-01
Series:International Journal of Infectious Diseases
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971219302620
id doaj-9de5045bb41745ba84c0df0e2515a0a8
record_format Article
spelling doaj-9de5045bb41745ba84c0df0e2515a0a82020-11-24T23:54:37ZengElsevierInternational Journal of Infectious Diseases1201-97122019-08-0185203211National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United StatesVikas Gupta0Gang Ye1Melanie Olesky2Kenneth Lawrence3John Murray4Kalvin Yu5Becton, Dickinson and Company, Franklin Lakes, NJ, United States; Corresponding author at: Becton, Dickinson and Company, 1 Becton Drive, Franklin Lakes, NJ, 07417, United States.Becton, Dickinson and Company, Franklin Lakes, NJ, United StatesTetraphase Pharmaceuticals, Watertown, MA, United StatesTetraphase Pharmaceuticals, Watertown, MA, United StatesBecton, Dickinson and Company, Franklin Lakes, NJ, United StatesBecton, Dickinson and Company, Franklin Lakes, NJ, United StatesObjectives: To determine antimicrobial nonsusceptibility rates for Enterobacteriaceae and Acinetobacter spp. in US hospitals. Methods: We analyzed antimicrobial susceptibilities of non-duplicate Enterobacteriaceae and Acinetobacter spp. isolates reported in 2017 from 375 US hospitals in the BD Insights Research Database. Logistic and Poisson regression modeling methods were used to estimate proportions of resistant isolates and rates per 1000 hospital admissions. National projections were generated based on raking (weighting) methods. Results: The nationwide proportions of resistant isolates in inpatients were an estimated 12.6%, 6.6%, and 1.2% for Enterobacteriaceae with extended-spectrum beta-lactamase (ESBL), multidrug resistant (MDR), and carbapenem-nonsusceptible (Carb-NS) phenotypes, respectively, and 42.4% and 34.5% for Acinetobacter spp. with MDR and Carb-NS phenotypes. Resistance varied by geographic region and hospital size/type. Estimated nationwide rates per 1000 hospital admissions ranged from a high of 7.1 for ESBL Enterobacteriaceae to a low of 0.3 for Carb-NS Acinetobacter spp. The estimated number of isolates occurring in US inpatients each year was 290,220 ESBL, 173,984 MDR, and 30,194 Carb-NS for Enterobacteriaceae and 12,274 MDR and 9,991 Carb-NS for Acinetobacter spp. Conclusions: National prevalence estimates suggest high levels of antimicrobial resistance and a substantial number of patients with resistant Enterobacteriaceae and Acinetobacter spp. in US hospitals. Keywords: Antimicrobial resistance, Susceptibility, Enterobacteriaceae, Acinetobacter, United States, Prevalencehttp://www.sciencedirect.com/science/article/pii/S1201971219302620
collection DOAJ
language English
format Article
sources DOAJ
author Vikas Gupta
Gang Ye
Melanie Olesky
Kenneth Lawrence
John Murray
Kalvin Yu
spellingShingle Vikas Gupta
Gang Ye
Melanie Olesky
Kenneth Lawrence
John Murray
Kalvin Yu
National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States
International Journal of Infectious Diseases
author_facet Vikas Gupta
Gang Ye
Melanie Olesky
Kenneth Lawrence
John Murray
Kalvin Yu
author_sort Vikas Gupta
title National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States
title_short National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States
title_full National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States
title_fullStr National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States
title_full_unstemmed National prevalence estimates for resistant Enterobacteriaceae and Acinetobacter species in hospitalized patients in the United States
title_sort national prevalence estimates for resistant enterobacteriaceae and acinetobacter species in hospitalized patients in the united states
publisher Elsevier
series International Journal of Infectious Diseases
issn 1201-9712
publishDate 2019-08-01
description Objectives: To determine antimicrobial nonsusceptibility rates for Enterobacteriaceae and Acinetobacter spp. in US hospitals. Methods: We analyzed antimicrobial susceptibilities of non-duplicate Enterobacteriaceae and Acinetobacter spp. isolates reported in 2017 from 375 US hospitals in the BD Insights Research Database. Logistic and Poisson regression modeling methods were used to estimate proportions of resistant isolates and rates per 1000 hospital admissions. National projections were generated based on raking (weighting) methods. Results: The nationwide proportions of resistant isolates in inpatients were an estimated 12.6%, 6.6%, and 1.2% for Enterobacteriaceae with extended-spectrum beta-lactamase (ESBL), multidrug resistant (MDR), and carbapenem-nonsusceptible (Carb-NS) phenotypes, respectively, and 42.4% and 34.5% for Acinetobacter spp. with MDR and Carb-NS phenotypes. Resistance varied by geographic region and hospital size/type. Estimated nationwide rates per 1000 hospital admissions ranged from a high of 7.1 for ESBL Enterobacteriaceae to a low of 0.3 for Carb-NS Acinetobacter spp. The estimated number of isolates occurring in US inpatients each year was 290,220 ESBL, 173,984 MDR, and 30,194 Carb-NS for Enterobacteriaceae and 12,274 MDR and 9,991 Carb-NS for Acinetobacter spp. Conclusions: National prevalence estimates suggest high levels of antimicrobial resistance and a substantial number of patients with resistant Enterobacteriaceae and Acinetobacter spp. in US hospitals. Keywords: Antimicrobial resistance, Susceptibility, Enterobacteriaceae, Acinetobacter, United States, Prevalence
url http://www.sciencedirect.com/science/article/pii/S1201971219302620
work_keys_str_mv AT vikasgupta nationalprevalenceestimatesforresistantenterobacteriaceaeandacinetobacterspeciesinhospitalizedpatientsintheunitedstates
AT gangye nationalprevalenceestimatesforresistantenterobacteriaceaeandacinetobacterspeciesinhospitalizedpatientsintheunitedstates
AT melanieolesky nationalprevalenceestimatesforresistantenterobacteriaceaeandacinetobacterspeciesinhospitalizedpatientsintheunitedstates
AT kennethlawrence nationalprevalenceestimatesforresistantenterobacteriaceaeandacinetobacterspeciesinhospitalizedpatientsintheunitedstates
AT johnmurray nationalprevalenceestimatesforresistantenterobacteriaceaeandacinetobacterspeciesinhospitalizedpatientsintheunitedstates
AT kalvinyu nationalprevalenceestimatesforresistantenterobacteriaceaeandacinetobacterspeciesinhospitalizedpatientsintheunitedstates
_version_ 1725465640918056960